Novo Nordisk cuts Ozempic and Wegovy prices up to 48% in India

Novo Nordisk (NYSE: NVO) reduced prices of its diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% respectively in India, the company said Tuesday.

The Danish pharmaceutical company implemented the price cuts to compete with local drugmakers offering generic versions of the medications in the Indian market.

You May Also Be Interested In

• SK Hynix CEO: memory chip shortage may persist beyond 2030, 2027 will be the worst year
• Park Aerospace names John Jamieson as senior VP and general manager
• Popular stocks with increasing option volume: MU SOFI PLTR INTC NFLX MSTR SPCX HOOD ORCL